Mylan launches generic Klor-Con

PITTSBURGH — Mylan on Friday announced the launch of potassium chloride extended-release tablets, USP in 600-mg and 750-mg dosage strengths. The drug is the generic version of Klor-Con from Upsher-Smith and is used for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis, the company stated.



Potassium chloride extended-release tablets, USP had sales in the United States of $135 million for the 12 months ending June 30, 2014, according to IMS Health data.